ES2877754T3 - Nuevas proteasas estreptocócicas - Google Patents
Nuevas proteasas estreptocócicas Download PDFInfo
- Publication number
- ES2877754T3 ES2877754T3 ES17703958T ES17703958T ES2877754T3 ES 2877754 T3 ES2877754 T3 ES 2877754T3 ES 17703958 T ES17703958 T ES 17703958T ES 17703958 T ES17703958 T ES 17703958T ES 2877754 T3 ES2877754 T3 ES 2877754T3
- Authority
- ES
- Spain
- Prior art keywords
- igg
- igde
- suis
- cleavage
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000035195 Peptidases Human genes 0.000 title description 37
- 108091005804 Peptidases Proteins 0.000 title description 37
- 239000004365 Protease Substances 0.000 title description 36
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 84
- 230000007017 scission Effects 0.000 claims abstract description 83
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 73
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 72
- 229920001184 polypeptide Polymers 0.000 claims abstract description 71
- 230000000694 effects Effects 0.000 claims abstract description 67
- 108010005843 Cysteine Proteases Proteins 0.000 claims abstract description 43
- 102000005927 Cysteine Proteases Human genes 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000012634 fragment Substances 0.000 claims abstract description 25
- 238000000338 in vitro Methods 0.000 claims abstract description 11
- 150000001413 amino acids Chemical group 0.000 claims description 33
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 238000004458 analytical method Methods 0.000 claims description 12
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 7
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 7
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 7
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 7
- 238000004949 mass spectrometry Methods 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 34
- 241000194021 Streptococcus suis Species 0.000 description 83
- 108090000623 proteins and genes Proteins 0.000 description 53
- 102000004169 proteins and genes Human genes 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 40
- 108091033319 polynucleotide Proteins 0.000 description 39
- 102000040430 polynucleotide Human genes 0.000 description 39
- 239000002157 polynucleotide Substances 0.000 description 39
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 36
- 239000007857 degradation product Substances 0.000 description 28
- 238000001262 western blot Methods 0.000 description 25
- 239000012228 culture supernatant Substances 0.000 description 20
- 235000019419 proteases Nutrition 0.000 description 20
- 230000000593 degrading effect Effects 0.000 description 19
- 238000006731 degradation reaction Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 17
- 230000015556 catabolic process Effects 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 241000283073 Equus caballus Species 0.000 description 15
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 241000194017 Streptococcus Species 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 241000194053 Streptococcus porcinus Species 0.000 description 11
- 230000003197 catalytic effect Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 241000193985 Streptococcus agalactiae Species 0.000 description 10
- 241000194048 Streptococcus equi Species 0.000 description 10
- 241001400864 Streptococcus pseudoporcinus Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 241000282887 Suidae Species 0.000 description 7
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 7
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000002797 proteolythic effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 206010061372 Streptococcal infection Diseases 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108010080638 N-benzyloxycarbonyl-leucyl-valyl-glycine diazomethane Proteins 0.000 description 5
- 108060008539 Transglutaminase Proteins 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 102000003601 transglutaminase Human genes 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 208000033365 congenital hypomelinating neuropathy Diseases 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000002169 hydrotherapy Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101710136329 IgM protease Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 101710108485 Envelope phospholipase F13 Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 241001624361 Streptococcus suis P1/7 Species 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 208000013633 acquired hemophilia Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- -1 aliphatic amino acid Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000002017 Autoimmune Hypophysitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 208000035900 Autoimmune polyendocrinopathy type 1 Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 208000029468 Autoimmune polyendocrinopathy type 3 Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 1
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 229940094664 Cysteine protease inhibitor Drugs 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 108091020100 Gingipain Cysteine Endopeptidases Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 241000579835 Merops Species 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 108010082913 S-layer proteins Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000573651 Streptococcus merionis Species 0.000 description 1
- 241000849115 Streptococcus suis 05ZYH33 Species 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000020176 autoimmune hypoparathyroidism Diseases 0.000 description 1
- 208000006424 autoimmune oophoritis Diseases 0.000 description 1
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 108700017365 bacteria SspA Proteins 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 239000007382 columbia agar Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 208000011610 primary hypophysitis Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/641—Cysteine endopeptidases (3.4.22)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Bioinformatics & Computational Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1630021 | 2016-02-04 | ||
| PCT/EP2017/052463 WO2017134274A1 (en) | 2016-02-04 | 2017-02-03 | New streptococcal proteases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2877754T3 true ES2877754T3 (es) | 2021-11-17 |
Family
ID=57995190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17703958T Active ES2877754T3 (es) | 2016-02-04 | 2017-02-03 | Nuevas proteasas estreptocócicas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12006530B2 (https=) |
| EP (1) | EP3411389B1 (https=) |
| JP (2) | JP7123801B2 (https=) |
| KR (1) | KR102704583B1 (https=) |
| CN (1) | CN109311951B (https=) |
| AU (1) | AU2017214441B2 (https=) |
| CA (1) | CA3013527C (https=) |
| DK (1) | DK3411389T3 (https=) |
| ES (1) | ES2877754T3 (https=) |
| PL (1) | PL3411389T3 (https=) |
| PT (1) | PT3411389T (https=) |
| SG (1) | SG11201806639VA (https=) |
| WO (1) | WO2017134274A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12546782B2 (en) | 2013-03-15 | 2026-02-10 | Mayo Foundation For Medical Education And Research | Identification and monitoring of monoclonal immunoglobulins related to monoclonal gammopathy by molecular mass with mass spectrometry |
| CA2944767C (en) | 2014-04-04 | 2022-07-12 | Mayo Foundation For Medical Education And Research | Isotyping immunoglobulins using accurate molecular mass |
| EP3353200A4 (en) | 2015-09-24 | 2019-06-26 | Mayo Foundation for Medical Education and Research | IDENTIFICATION OF FREE LIGHT CHAINS FROM IMMOBILIZED LOBULIN BY MASS SPECTROMETRY |
| AU2017214441B2 (en) | 2016-02-04 | 2021-08-19 | Genovis Ab | New Streptococcal proteases |
| AU2017325022B2 (en) | 2016-09-07 | 2022-10-13 | Mayo Foundation For Medical Education And Research | Identification and monitoring of cleaved immunoglobulins by molecular mass |
| CN111183220B (zh) | 2017-05-26 | 2024-03-22 | 杰诺维斯公司 | 用于聚糖分析的工具 |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| US12153052B2 (en) | 2017-09-13 | 2024-11-26 | Mayo Foundation For Medical Education And Research | Identification and monitoring of immunoglobulin J chains |
| US11946937B2 (en) | 2017-09-13 | 2024-04-02 | Mayo Foundation For Medical Education And Research | Identification and monitoring of apoptosis inhibitor of macrophage |
| EP3723794A1 (en) * | 2017-12-15 | 2020-10-21 | Intervet International B.V. | A vaccine for protection against streptococcus suis |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| JP2023514204A (ja) | 2020-02-14 | 2023-04-05 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | Ｃｄｋｌ５欠損障害を処置するための遺伝子治療 |
| GB202002072D0 (en) * | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| WO2021254479A1 (zh) * | 2020-06-18 | 2021-12-23 | 上海宝济药业有限公司 | 一种免疫球蛋白降解酶IdeE的突变体 |
| CA3195177A1 (en) | 2020-10-07 | 2022-04-14 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i) |
| WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| US20240271115A1 (en) * | 2021-06-15 | 2024-08-15 | The University Of North Carolina At Chapel Hill | Methods and compositions for depleting antibodies |
| US20250019721A1 (en) | 2021-08-11 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| US20240424077A1 (en) * | 2021-11-18 | 2024-12-26 | Intervet Inc. | A method to produce a vaccine against streptococcus suis and the said vaccine |
| JPWO2024111657A1 (https=) * | 2022-11-25 | 2024-05-30 | ||
| JPWO2025047641A1 (https=) * | 2023-08-25 | 2025-03-06 | ||
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| GB202413764D0 (en) | 2024-09-18 | 2024-10-30 | Genovis Ab | Immunoglobulin proteases and their uses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2824074A1 (fr) * | 2001-04-26 | 2002-10-31 | Pasteur Institut | Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques |
| GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| JP2008525033A (ja) | 2004-12-22 | 2008-07-17 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | Ｂ群連鎖球菌 |
| PL1901773T3 (pl) | 2005-06-09 | 2012-09-28 | Hansa Medical Ab | Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu |
| DK2190984T3 (da) | 2007-09-14 | 2013-12-02 | Genovis Ab | Fremgangsmåder og kits til oprensning og påvisning af glycosyleret IgG |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| AU2017214441B2 (en) | 2016-02-04 | 2021-08-19 | Genovis Ab | New Streptococcal proteases |
-
2017
- 2017-02-03 AU AU2017214441A patent/AU2017214441B2/en active Active
- 2017-02-03 KR KR1020187025476A patent/KR102704583B1/ko active Active
- 2017-02-03 EP EP17703958.3A patent/EP3411389B1/en active Active
- 2017-02-03 CA CA3013527A patent/CA3013527C/en active Active
- 2017-02-03 SG SG11201806639VA patent/SG11201806639VA/en unknown
- 2017-02-03 PT PT177039583T patent/PT3411389T/pt unknown
- 2017-02-03 WO PCT/EP2017/052463 patent/WO2017134274A1/en not_active Ceased
- 2017-02-03 US US16/075,059 patent/US12006530B2/en active Active
- 2017-02-03 CN CN201780022485.6A patent/CN109311951B/zh active Active
- 2017-02-03 PL PL17703958T patent/PL3411389T3/pl unknown
- 2017-02-03 ES ES17703958T patent/ES2877754T3/es active Active
- 2017-02-03 DK DK17703958.3T patent/DK3411389T3/da active
- 2017-02-03 JP JP2018540841A patent/JP7123801B2/ja active Active
-
2022
- 2022-03-30 JP JP2022056522A patent/JP2022115853A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022115853A (ja) | 2022-08-09 |
| PT3411389T (pt) | 2021-06-28 |
| CN109311951A (zh) | 2019-02-05 |
| CA3013527C (en) | 2023-09-05 |
| JP2019506866A (ja) | 2019-03-14 |
| KR102704583B1 (ko) | 2024-09-06 |
| US20190345533A1 (en) | 2019-11-14 |
| DK3411389T3 (da) | 2021-06-21 |
| AU2017214441B2 (en) | 2021-08-19 |
| US12006530B2 (en) | 2024-06-11 |
| EP3411389A1 (en) | 2018-12-12 |
| JP7123801B2 (ja) | 2022-08-23 |
| CN109311951B (zh) | 2022-10-11 |
| KR20180124857A (ko) | 2018-11-21 |
| EP3411389B1 (en) | 2021-03-24 |
| WO2017134274A1 (en) | 2017-08-10 |
| CA3013527A1 (en) | 2017-08-10 |
| AU2017214441A1 (en) | 2018-08-16 |
| SG11201806639VA (en) | 2018-09-27 |
| PL3411389T3 (pl) | 2021-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2877754T3 (es) | Nuevas proteasas estreptocócicas | |
| Roberts et al. | Novel expression of Haemonchus contortus vaccine candidate aminopeptidase H11 using the free-living nematode Caenorhabditis elegans | |
| Song et al. | The immune protection induced by a serine protease inhibitor from the foodborne parasite Trichinella spiralis | |
| JP6100826B2 (ja) | 黄色ブドウ球菌由来のポリペプチド及び使用方法 | |
| Zhang et al. | Molecular characterization of Trichinella spiralis aminopeptidase and its potential as a novel vaccine candidate antigen against trichinellosis in BALB/c mice | |
| Pearson et al. | An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection | |
| Horta et al. | Molecular, immunological, and biological characterization of Tityus serrulatus venom hyaluronidase: new insights into its role in envenomation | |
| WO2015042423A2 (en) | Vaccine | |
| Tang et al. | Characterisation of a high-frequency gene encoding a strongly antigenic cystatin-like protein from Trichinella spiralis at its early invasion stage | |
| Spoerry et al. | Identification and characterization of IgdE, a novel IgG-degrading protease of Streptococcus suis with unique specificity for porcine IgG | |
| Subharat et al. | Vaccination of sheep with a methanogen protein provides insight into levels of antibody in saliva needed to target ruminal methanogens | |
| Redmond et al. | An immunogenic cathepsin F secreted by the parasitic stages of Teladorsagia circumcincta | |
| Yan et al. | Vaccination of goats with DNA vaccine encoding Dim-1 induced partial protection against Haemonchus contortus: A preliminary experimental study | |
| Senawong et al. | Cloning, expression, and characterization of a novel Opisthorchis viverrini calcium-binding EF-hand protein | |
| Ntombela et al. | Production of recombinant lumpy skin disease virus A27L and L1R proteins for application in diagnostics and vaccine development | |
| Kang et al. | Identification and characterization of the second cysteine protease inhibitor of Clonorchis sinensis (CsStefin-2) | |
| Pakchotanon et al. | Molecular characterization of serine protease inhibitor isoform 3, SmSPI, from Schistosoma mansoni | |
| Misra et al. | Immunoproteomics to identify Staphylococcus aureus antigens expressed in bovine milk during mastitis | |
| Noon et al. | A highly expressed intestinal cysteine protease of Ancylostoma ceylanicum protects vaccinated hamsters from hookworm infection | |
| Yoonuan et al. | Molecular and immunological characterization of cathepsin L-like cysteine protease of Paragonimus pseudoheterotremus | |
| Redmond et al. | Further protection studies using recombinant forms of Haemonchus contortus cysteine proteinases | |
| Li et al. | Gene cloning, expression, and localization of antigen 5 in the life cycle of Echinococcus granulosus | |
| Kobayashi et al. | Functional activities of the Tsh protein from avian pathogenic Escherichia coli (APEC) strains | |
| Rodrigues et al. | Immunization of sheep with a recombinant vaccine containing immunogenic nontoxic domains of Clostridium perfringens alpha and beta toxins | |
| Kwon et al. | Recombinant adenylate kinase 3 from liver fluke Clonorchis sinensis for histochemical analysis and serodiagnosis of clonorchiasis |